What is the differential diagnosis for a 31-year-old male with elevated alanine aminotransferase (ALT) of 153 U/L and aspartate aminotransferase (AST) of 72 U/L?

Differential Diagnosis for Elevated Transaminases (ALT 153, AST 72)

This 31-year-old male has a hepatocellular pattern of injury (ALT > AST with ALT approximately 2× normal) that most commonly indicates non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease, viral hepatitis, or medication-induced liver injury. 1

Pattern Recognition

The ALT:AST ratio is approximately 2:1, which is characteristic of:

• NAFLD (most common cause in this age group)
• Chronic viral hepatitis (B or C)
• Medication/drug-induced hepatotoxicity
• Early alcohol-related liver disease (though advanced alcoholic hepatitis typically shows AST > ALT)

The magnitude of elevation (ALT ~3-4× upper limit of normal, assuming normal range ~30-40 U/L for males) represents mild-to-moderate hepatocellular injury 2, 1.

Systematic Evaluation Approach

Initial Serologic Testing (First-Line)

Regardless of symptom severity, test immediately for common hepatic diseases 2:

• Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody-IgM (HBcIgM)
• Hepatitis C antibody (consider HCV-RNA if high suspicion)
• Hepatitis A IgM (if acute presentation)

Risk Factor Assessment (Concurrent with Serology)

Metabolic factors (most prevalent cause) 3:

• Body mass index and waist circumference
• Features of metabolic syndrome: diabetes, hypertension, dyslipidemia
• Note: 69% of unexplained aminotransferase elevations are associated with obesity and metabolic syndrome 3

Alcohol consumption 3:

• Quantify daily/weekly intake precisely
• Even moderate consumption can cause transaminase elevation
• Combined with obesity, significantly increases risk

Medication/supplement history 2, 1:

• Prescription medications (statins, antibiotics, anticonvulsants)
• Over-the-counter medications (acetaminophen, NSAIDs)
• Herbal supplements and bodybuilding supplements
• Anabolic steroids (can elevate transaminases) 4

Second-Tier Testing (If Initial Workup Negative)

• Iron studies (ferritin, transferrin saturation) for hereditary hemochromatosis 1
• Autoimmune hepatitis markers: ANA, anti-smooth muscle antibody, immunoglobulins 1
• Ceruloplasmin for Wilson disease (essential in patients <40 years) 1
• Alpha-1 antitrypsin level and phenotype 1
• Thyroid function tests (hypothyroidism can cause mild elevations)
• Celiac serologies (tissue transglutaminase antibody)

Imaging

Abdominal ultrasound 2:

• Assess for hepatic steatosis (echobright liver)
• Exclude biliary obstruction
• Evaluate liver architecture

Critical Pitfalls to Avoid

1. Do not assume normal ALT means no disease: Current upper limits of normal may be too high; true healthy ALT is 29-33 U/L for males 1. This patient's ALT of 153 is clearly abnormal.

2. Do not wait for normalization: The outdated practice of "repeat in 6-8 weeks to see if it normalizes" delays diagnosis of chronic conditions like HCV and NAFLD, where transaminases may fluctuate but disease persists 5.

3. Do not overlook muscle injury: If patient engages in intense resistance training or has muscle symptoms, check creatine kinase (CK) and gamma-glutamyltransferase (GGT). Normal GGT with elevated CK suggests rhabdomyolysis rather than liver disease 4.

4. Consider macro-AST: In isolated AST elevation with negative workup, polyethylene glycol (PEG) precipitation test can identify benign macro-AST 6.

Most Likely Diagnoses in Order of Probability

1. Non-alcoholic fatty liver disease (if metabolic risk factors present) 3, 7
2. Alcohol-related liver disease (if significant consumption)
3. Chronic hepatitis C (often mild transaminase elevation)
4. Chronic hepatitis B (endemic areas or risk factors)
5. Medication/supplement-induced hepatotoxicity
6. Autoimmune hepatitis (less common but important not to miss)
7. Hereditary hemochromatosis (young male demographic)
8. Wilson disease (must exclude in patients <40 years)

When to Expedite Evaluation

Immediate comprehensive workup indicated if 2:

• Symptoms present (jaundice, abdominal pain, fatigue)
• Evidence of hepatic dysfunction (elevated bilirubin, prolonged PT/INR, low albumin)
• Physical signs of chronic liver disease (spider angiomata, palmar erythema, splenomegaly)

This patient requires full initial serologic panel now, not observation 5. The extent of abnormality (ALT 153) warrants complete evaluation to prevent progression to end-stage liver disease, which remains preventable with early diagnosis 5.